cannabidiol

Ligand id: 4150

Name: cannabidiol

Abbreviated name: CBD

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 0
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 40.46
Molecular weight 314.22
XLogP 6.34
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
In June 2018 the FDA approved an oral solution containing CBD as a treatment for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in paediatric patients who are ≥2 years old. Lennox-Gastaut and Dravet syndromes are rare, severe and debilitating forms of childhood epilepsy. This is the first treatment for Dravet syndrome to be approved. The Epidiolex® formulation (a liquid formulation of pure plant-derived CBD) was reported to have met its primary endpoint in Phase 3 clinical trials (see NCT02091375 and NCT02224703 for current trial details), which were designed to evaluate the ability of this cannibinoid to reduce convulsive seizures in children with Dravet syndrome. Prior to formal approval, Epidiolex® had both Orphan Drug Designation and Fast Track Designation from the US FDA for the treatment of Dravet syndrome. The EMA has granted orphan drug designation for the treatment of pediatric epilepsy syndromes (Dravet, Lennox-Gestaut, and West syndromes), GvHD, perinatal asphyxia and tuberous sclerosis.

Epidiolex® is also being evaluated in tuberous sclerosis complex, another rare and severe pediatric epilepsy disorder.
Click here to link to ClinicalTrials.gov's list of Phase 3 Epidiolex® trials.
The manufacturer of Epidiolex® is GW Pharmaceuticals and their pipeline page provides details of the other cannabinoid drug candidates and additional conditions that they are investigating.
Mechanism Of Action and Pharmacodynamic Effects
CBD is not an agonist at CB1 cannabinoid receptors. The molecular mechanisms of action of CBD are not precisely defined, but may involve multiple targets. For example, CBD has been shown to stimulate vanilloid pain receptors (TRPVs), and to modulate cellular uptake and enzymatic hydrolysis of endogenous anandamide, and these mechanisms may contribute towards the drug's pharmacological effects [1].